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Abstract
Objective
To study the early time course of major bleeding and its subtypes in patients with cerebral
ischemia on dual and single antiplatelet therapy.
Methods
We performed a post hoc analysis on individual patient data from 6 randomized clinical trials
(Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events [CAPRIE], Second Eu-
ropean Stroke Prevention Study [ESPS-2], Management of Atherothrombosis With Clopi-
dogrel in High-Risk Patients [MATCH], Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance [CHARISMA], European/Australasian
Stroke Prevention in Reversible Ischaemia Trial [ESPRIT], and Prevention Regimen for Ef-
fectively Avoiding Second Strokes [PRoFESS]) including 45,195 patients with a TIA or
noncardioembolic ischemic stroke. We studied incidence rates of bleeding per antiplatelet
regimen stratiﬁed by time from randomization (≤30, 31–90, 91–180, 181–365, >365 days). We
calculated incidence rates per trial and pooled estimates with random-eﬀects meta-analysis. We
performed Poisson regression to assess diﬀerences between time periods with adjustment for
age and sex.
Results
The incidence of major bleeding on aspirin plus clopidogrel and aspirin plus -dipyridamole was
highest in the ﬁrst 30 days, 5.8 and 4.9 per 100 person-years, respectively, and was signiﬁcantly
higher than at 31 to 90 days (rate ratio 1.98, 95% conﬁdence interval 1.16–3.40 for aspirin plus
clopidogrel; rate ratio 1.94, 95% conﬁdence interval 1.24–3.03 for aspirin plus dipyridamole).
Incidence rates on aspirin and clopidogrel monotherapy were 2.8 and 2.5 per 100 person-years,
respectively, in the ﬁrst 30 days, with no signiﬁcant change over time. The time course was
similar for gastrointestinal bleeds. There was no early excess of intracranial hemorrhage in
patients on either dual or single antiplatelet therapy.
Conclusion
Dual antiplatelet therapy is associated with high early risks of major and gastrointestinal
bleeding that decline after the ﬁrst month in trial cohorts.
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Antiplatelet drugs are widely applied in the secondary pre-
vention of cardiovascular disease. Although they successfully
reduce the risk of recurrent ischemic events,1 antiplatelet
drugs are associated with a small but relevant risk of serious
bleeding,1 which is reported to vary between 1%/y and 1.5%/
y.2,3 The prognosis of patients who have experienced
a bleeding event is worse, with higher all-cause and cardio-
vascular mortality.4 Given the wide application of antiplatelet
therapy and consequences of bleeding events, it is important
to gain more insight into the safety of antiplatelet agents.
It has been shown previously that the excess risk of major
bleeding on aspirin compared with placebo falls with time in
primary prevention trials, driven mainly by an excess early risk
of bleeding on aspirin.5 It is uncertain whether the time course
would be the same in the secondary prevention of cerebral
ischemia. In addition, it is unknown whether the time course
diﬀers for dual antiplatelet therapy, which is known to be
associated with higher risks of bleeding than monotherapy.6,7
Indeed, there is some preliminary evidence of a high early risk
of bleeding on dual antiplatelet treatment after TIA andminor
stroke, particularly among aspirin-naive patients,8 but larger
studies are required. We aimed to study the time course of
major bleeding events and their subtypes in patients with
cerebral ischemia on dual and single antiplatelet therapy.
Methods
Study population
We analyzed individual patient data from 6 randomized clinical
trials (Clopidogrel Versus Aspirin in Patients at Risk of
Ischaemic Events [CAPRIE], Second European Stroke Pre-
vention Study [ESPS-2], Management of Atherothrombosis
With Clopidogrel in High-Risk Patients [MATCH], Clopi-
dogrel for High Atherothrombotic Risk and Ischemic Stabili-
zation, Management, and Avoidance [CHARISMA],
European/Australasian Stroke Prevention in Reversible Is-
chaemia Trial [ESPRIT], and Prevention Regimen for Eﬀec-
tively Avoiding Second Strokes [PRoFESS]6,7,9–12)
investigating the eﬃcacy of antiplatelet agents in patients with
a TIA or ischemic stroke. Details of the individual patient data
meta-analysis have been described previously.13 In total, 48,023
patients with cerebral ischemia were included in the trials
between 1989 and 2006. Details of the included trials are
presented in table 1. Aspirin was studied in 4 trials (CAPRIE,
ESPS-2, CHARISMA, and ESPRIT), clopidogrel was studied
in 3 (CAPRIE, MATCH, and PRoFESS), aspirin in combi-
nation with (extended-release) dipyridamole was examined in
3 (ESPS-2, ESPRIT, and PRoFESS), and aspirin in combina-
tion with clopidogrel was assessed in 2 (MATCH and CHA-
RISMA). The ESPS-2 trial had 4 arms and randomized patients
to aspirin, aspirin plus extended-release dipyridamole,
extended-release dipyridamole only, or placebo. Median
follow-up ranged from 1.4 to 3.5 years.
We excluded patients with a possible cardioembolic origin of
their stroke (those with a history of atrial ﬁbrillation or Trial of
ORG 10172 in Acute Stroke Treatment classiﬁcation of car-
dioembolic stroke). We used trial-speciﬁc deﬁnitions for
major bleeding.Major bleeding events included bleedings that
were fatal, intracranial, or signiﬁcantly disabling or required
hospital admission. Intracranial bleeding events included in-
tracerebral hemorrhages, subarachnoid hemorrhages, and
subdural and epidural hematomas. Hemorrhagic trans-
formations of ischemic strokes were not counted as in-
tracranial hemorrhages. Gastrointestinal bleeding events
included upper and lower gastrointestinal bleeds that were
fatal or required hospital admission.
Statistical analysis
We restricted our analyses to patients who were on treat-
ment. For patients who permanently discontinued trial
medication, on-treatment time was deﬁned as time until last
intake of study drugs plus 28 days. For patients who com-
pleted the trial, on-treatment time was the same as
intention-to-treat time. We calculated incidence rates of
bleeding per antiplatelet regimen stratiﬁed by time from
randomization (≤30, 31–90, 91–180, 181–365, and >365
days). Incidence rates were calculated for each trial sepa-
rately and were subsequently pooled per antiplatelet regi-
men with random-eﬀects meta-analysis. We performed
Poisson regression analysis to quantify the diﬀerence be-
tween time periods with adjustment for age and sex. Rate
ratios were calculated per trial and subsequently pooled per
antiplatelet regimen with random-eﬀects meta-analysis. The
time period of 31 to 90 days was chosen as the reference
category in all analyses. We examined the inﬂuence of age
Glossary
CAPRIE = Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events; CHANCE = Clopidogrel in High-Risk
Patients With Acute Nondisabling Cerebrovascular Events; CHARISMA = Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance; CI = conﬁdence interval; ESPRIT = European/Australasian Stroke
Prevention in Reversible Ischaemia Trial; ESPS-2 = Second European Stroke Prevention Study; EXPRESS = Eﬀect of Urgent
Treatment of Transient Ischemic Attack and Minor Stroke on early Recurrent Stroke; FASTER = Fast Assessment of Stroke
and Transient Ischaemic Attack to Prevent Early Recurrence; MATCH = Management of Atherothrombosis With
Clopidogrel in High-Risk Patients; PRoFESS = Prevention Regimen for Eﬀectively Avoiding Second Strokes;RR = rate ratio;
SPS3 = Secondary Prevention of Small Subcortical Strokes Trial; TARDIS = Triple Antiplatelets for Reducing Dependency
in Ischaemic Stroke.
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and prior antiplatelet drug use on the time course of
bleeding by performing stratiﬁed analyses. Deﬁnitions of
prior antiplatelet drug use varied considerably across trials;
therefore, we used prior vascular disease as a proxy for long-
term prior antiplatelet drug use, which we deﬁned as
a medical history of stroke, TIA, myocardial infarction,
angina, or peripheral artery disease. All analyses were per-
formed with R version 3.2.2.
Standard protocol approvals, registrations,
and patients consents
The trials were approved by the ethics committee or in-
stitutional review board at each participating center, and all
patients gave written informed consent.
Results
After the exclusion of patients with a possible cardioembolic
stroke (n = 1,829) and patients who permanently dis-
continued treatment but for whom the date of last intake was
unknown (n = 999; rate of major bleeding 0.8 per 100 person-
years), 45,195 patients remained for the analysis. During
82,199 person-years of follow-up, 1,338 major bleedings, 324
intracranial bleedings, and 618 gastrointestinal bleedings oc-
curred. Baseline characteristics of patients are presented in
table 2.
The time course of major bleeding per antiplatelet regimen
is displayed in ﬁgure 1. The risk of major bleeding was
highest during the ﬁrst 30 days for all antiplatelet regimens
except for dipyridamole only. The incidence rate was 2.8 per
100 person-years for aspirin, 2.5 per 100 person-years for
clopidogrel, 4.9 per 100 person-years for aspirin plus
dipyridamole, and 5.8 per 100 person-years for aspirin plus
clopidogrel (ﬁgure e-1, http://links.lww.com/WNL/A167).
Results per trial are shown in ﬁgures e-2 through e-6. In
Table 1 Overview of included trials
Trial, year
Recruitment
period No. Intervention
Time to
randomization,
median (IQR), d Inclusion criteria
Mean
age
(SD), y
Follow-up,
median
(range), y
CAPRIE, stroke
subgroup, 1996
1992–1995 6,431 C vs A 34 (16–80) IS within 6 mo 65 (11.1) 2.0 (0–3.3)
ESPS-2, 1996 1989–1993 6,602 A+D vs A vsD
vs placebo
22 (9–48) TIA/IS within 3 mo 67 (11.1) 2.0 (0–5.7)
MATCH, 2004 2000–2002 7,599 A + C vs C 15 (8–39) TIA/IS within 3 mo and 1
additional vascular risk factor
within 3 y
66 (9.9) 1.5 (0–1.5)
CHARISMA,
stroke
subgroup, 2006
2002–2003 4,320 A + C vs A 126 (19–510) TIA/IS within 5 y; age ≥45 y 65 (9.8) 2.1 (0–2.9)
ESPRIT, 2006 1997–2005 2,739 A + D vs A 50 (21–84) TIA/minor IS within 6 mo 63 (10.9) 3.4 (0–8.1)
PRoFESS, 2008 2003–2006 20,332 A + D vs C 15 (7–39) IS within 3 mo; clinically and
neurologically stable; age ≥55 y
66 (8.6) 2.4 (0–4.4)
Abbreviations: A = aspirin; C = clopidogrel; CAPRIE = Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events; CHARISMA = Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; D = dipyridamole; ESPRIT = European/Australasian Stroke Prevention in
Reversible Ischaemia Trial; ESPS-2 = Second European Stroke PreventionStudy; IQR = interquartile range; IS = ischemic stroke; MATCH = Management of
Atherothrombosis With Clopidogrel in High-Risk Patients With Recent TIA or Ischaemic Stroke.
Table 2 Baseline characteristics of 45,195 patients
included in the analyses
No. (%)
Mean age (SD), y 65.5 (9.8)
Male sex 28,595 (63)
Qualifying event
TIA 5,013 (11)
Ischemic stroke 40,179 (89)
Current smoking 10,116 (22)
Hypertension 33,325 (74)
Diabetes mellitus 14,579 (32)
Prior stroke 7,375 (17)
Prior myocardial infarction 3,341 (7)
Prior vascular disease 17,909 (40)
Type of antiplatelet
Aspirin 8,103 (18)
Clopidogrel 16,084 (36)
Aspirin + dipyridamole 12,218 (27)
Aspirin + clopidogrel 5,754 (13)
Dipyridamole 1,521 (3)
Placebo 1,515 (3)
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patients on dual antiplatelet therapy, the risk of major
bleeding was signiﬁcantly higher in the ﬁrst 30 days com-
pared with 31 to 90 days (rate ratio [RR] 1.98, 95% conﬁ-
dence interval [CI] 1.16–3.40 for aspirin plus clopidogrel;
RR 1.94, 95% CI 1.24–3.03 for aspirin plus dipyridamole,
table 3). No signiﬁcant change over time was seen for
single antiplatelet regimens (RR 1.27, 95% CI 0.69–2.37 for
aspirin; RR 1.28, 95% CI 0.66–2.48 for clopidogrel; and RR
0.87, 95% CI 0.12–4.44 for dipyridamole, table 3). The same
patterns were seen for gastrointestinal bleeds (ﬁgure 2A).
Risk of intracranial hemorrhage was stable over time
(ﬁgure 2B and table e-1, http://links.lww.com/WNL/A168).
Pooled incidence rates of gastrointestinal and intracranial
bleeding per antiplatelet regimen are presented in ﬁgures e-7
and e-8.
Among elderly patients (age ≥65 years), absolute risks of
major bleeding were higher. The time course of the risk of
bleeding was comparable for younger and older patients
(ﬁgure e-9, http://links.lww.com/WNL/A167). A total of
17,909 patients (40%) had a diagnosis of vascular disease
before their presenting event. Patterns of bleeding risk over
time were essentially similar for patients with and without
prior vascular disease (ﬁgure e-10).
Figure 1 Time course of major bleeding per antiplatelet regimen (pooled estimates)
(A) Single antiplatelet therapy (APT), (B) dual APT, and (C) dipyridamole and placebo.
Table 3 Adjusted rate ratios (95% confidence interval) for major bleeding
0–30 d 31–90 d 91–180 d 181–365 d >365 d
Aspirin 1.27 (0.69–2.37) 1 (Referent) 0.74 (0.40–1.34) 0.84 (0.44–1.61) 0.82 (0.54–1.27)
Clopidogrel 1.28 (0.66–2.48) 1 (Referent) 0.82 (0.55–1.21) 0.77 (0.44–1.36) 0.74 (0.42–1.29)
Aspirin + dipyridamole 1.94 (1.24–3.03) 1 (Referent) 0.66 (0.42–1.03) 0.62 (0.42–0.91) 0.62 (0.44–0.87)
Aspirin + clopidogrel 1.98 (1.16–3.40) 1 (Referent) 0.92 (0.39–2.18) 0.84 (0.53–1.34) 0.84 (0.53–1.33)
Dipyridamole 0.87 (0.12–4.44) 1 (Referent) 0.93 (0.25–3.76) 0.52 (0.14–2.08) 0.28 (0.07–1.14)
Placebo 4.59 (0.99–32.1) 1 (Referent) 2.16 (0.50–14.8) 1.19 (0.27–8.10) 0.66 (0.15–4.50)
Adjusted for age and sex.
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Discussion
Our study showed high early risks of major bleeding and,
more speciﬁcally, gastrointestinal bleeding on dual anti-
platelet therapy that decline over time. There was no early
excess risk of intracranial hemorrhages among patients on
either dual antiplatelet therapy or monotherapy.
Multiple trials have shown the increased risk of major
bleeding associated with long-term dual antiplatelet therapy
after stroke: MATCH, CHARISMA, and Secondary Pre-
vention of Small Subcortical Strokes Trial (SPS3) demon-
strated that aspirin plus clopidogrel is associated with
statistically signiﬁcant higher bleeding risks than either of the
regimens separately.6,7,14 Furthermore, the PRoFESS trial
showed that aspirin plus dipyridamole led to more major and
intracranial bleedings than clopidogrel monotherapy.12 Re-
cent trials have investigated the beneﬁt of a short course of
aspirin plus clopidogrel, aiming to reduce the risk of early
recurrent strokes without exposing patients to long-term dual
antiplatelet treatment. Combination therapy was shown to be
more protective against ischemic events than monotherapy,
but results regarding risk of bleeding in the early phase
were conﬂicting.15,16 While the Clopidogrel in High-Risk
Patients With Acute Nondisabling Cerebrovascular Events
(CHANCE) trial showed similar risks of bleeding among
both groups,15 the Fast Assessment of Stroke and Transient
Ischaemic Attack to Prevent Early Recurrence (FASTER)
Figure 2 Time course of (A) gastrointestinal bleeding and(B) intracranial bleeding per antiplatelet regimen (pooled
estimates)
APT = antiplatelet therapy.
Neurology.org/N Neurology | Volume 90, Number 8 | February 20, 2018 e687
trial showed a signiﬁcantly higher risk of symptomatic and
asymptomatic bleeds among patients treated with dual anti-
platelet therapy.16 The recent Triple Antiplatelets for Re-
ducing Dependency in Ischaemic Stroke (TARDIS) trial
compared short-term triple therapy (aspirin plus dipyr-
idamole plus clopidogrel) with guideline-based therapy and
found no net clinical beneﬁt due to an excess of bleeding
complications with triple antiplatelet therapy.17
Evidence for a time course of bleeding risk is scarce. Post hoc
analyses on data from CHARISMA showed that the excess risk
of bleeding on aspirin plus clopidogrel was greatest in the ﬁrst
year and similar to aspirin thereafter.18,19 This is in line with our
results indicating high early risks on dual antiplatelet therapy
that decline over time. Results from this study and ours suggest
that some form of resistance to antiplatelet drugs occurs over
time. Previous studies investigating platelet response over time
have shown conﬂicting results. Some reported stable platelet
reactivity,20 while others showed decreased platelet inhibi-
tion after the ﬁrst months of exposure to both aspirin and
clopidogrel.21–23 The mechanisms that cause this reduced
sensitivity over time remain unclear. Possibly, upregulation of
other pathways that mediate platelet aggregation may play
a role. Our ﬁndings may also suggest that patients who are
prone to bleeding experience a bleed shortly after the start of
treatment, leaving a cohort that is at relatively lower risk. Al-
ternatively, the high early risk may be explained partly by the
natural history of bleeds as suggested by the time course in
placebo-treated patients. However, the number of bleeds in the
placebo group was small, and analyses of other data sources are
required to better understand the natural history of bleeding
after stroke.
High bleeding risks on aspirin plus clopidogrel have been
reported previously and are a cause for concern. A post hoc
analysis on data from the Eﬀect of Urgent Treatment of
Transient Ischemic Attack and Minor Stroke on early Re-
current Stroke (EXPRESS) study and FASTER pilot trial
showed excessive risks during the ﬁrst 90 days, particularly
among aspirin-naive patients.8 Whether the risk decreased
over time was not investigated. The high observed risks were
attributed partly to the fact that patients were vulnerable
shortly after their TIA or ischemic stroke. However, our data
show that after the acute phase of TIA or stroke, initiation of
dual antiplatelet therapy is accompanied by a doubling of risk
in the ﬁrst 30 days.
Our study addresses the time course of gastrointestinal and
intracranial bleeding separately. The ﬁnding that aggressive
antiplatelet therapy has a more pronounced eﬀect on gas-
trointestinal bleeding is plausible because patients with
inherited and acquired platelet disorders often present with
mucocutaneous bleeding patterns.24
A strength of our study is the large sample size with a large
number of bleeding events. In addition, the quality of the data
was high, with regular follow-up and adjudication of events by
an independent committee. Furthermore, we were able to
restrict our analysis to patients who were on treatment,
thereby reducing the possibility that our ﬁndings reﬂect poor
compliance. Our study also has limitations. First, we did not
have data on other antiplatelet agents such as cilostazol, ter-
utroban, or triﬂusal. However, the antiplatelet drugs in-
vestigated in our study are those recommended as ﬁrst-line
agents in current guidelines.25,26 Second, absolute risks of
bleeding may have been underestimated because patients at
highest bleeding risk were excluded from the trials. It is also
possible that the time course of bleeding risk might diﬀer in
older or frailer populations. Third, control of medication in-
take was not performed in all trials; therefore, we cannot
exclude that patients who were included in the on-treatment
analyses in reality did not take their medication anymore.
Finally, we performed a post hoc analysis on trial data, and
although adjustment for age and sex did not change the
results, the possibility of residual confounding remains.
The risk of major bleeding and, more speciﬁcally, gastroin-
testinal bleeding is increased 2-fold in the ﬁrst month on dual
antiplatelet treatment. The risk of intracranial hemorrhage is
stable over time. Although the risk of early recurrent ischemic
events will likely outweigh the risk of bleeding, our ﬁndings
draw attention to the high early risks of bleeding associated
with dual antiplatelet therapy, which may have previously
been underestimated. The high early risks may warrant the
initiation of gastroprotective agents in patients on dual anti-
platelet therapy, as well as close monitoring of patients in the
early phase.
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Study question
Does the early time course of major bleeding events in patients
with cerebral ischemia diﬀer between those prescribed dual anti-
platelet therapy and those prescribed single antiplatelet therapy?
Summary answer
Dual antiplatelet therapy is associated with a high risk of major
bleeding that declines after the ﬁrst month. The risk of major
bleeding on single antiplatelet therapy does not change over time.
What is known and what this paper adds
Antiplatelet therapy after ischemic stroke is associated with a small
increase in the risk of major bleeding, and dual antiplatelet therapy
aggravates this risk. Preliminary evidence suggests that risk of
bleeding on dual therapymay be particularly high early after the start
of treatment. This study provides evidence from a large cohort that
conﬁrms the greater risk of dual antiplatelet therapy early after
initiation.
Participants and setting
This study analyzed data from 45,195 patients with a TIA or
noncardioembolic ischemic stroke who participated in any of 6
RCTs conducted between 1989 and 2006 that examined the
eﬃcacies of diﬀerent antiplatelet therapies.
Design, size, and duration
The study retrospectively meta-analyzed data from the 6 RCTs to
determine how drug exposures aﬀected outcomes. Of the patients,
8,103 (18%) received aspirin alone, 16,084 (36%) received clopi-
dogrel alone, 1,521 (3%) received dipyridamole alone, 12,218 (27%)
received aspirin-dipyridamole therapy, 5,754 (13%) received aspirin-
clopidogrel therapy, and 1,515 (3%) received placebo treatments.
Primary outcomes
The primary outcome was a major bleeding event, which was
deﬁned as being fatal, intracranial, or substantially disabling or
necessitating hospitalization.
Main results and the role of chance
During 82,199 person-years of follow-up, there were 1,338 major
bleeding events. Incidence rates within the ﬁrst 30 days were
higher for aspirin-dipyridamole therapy (4.9 per 100 person-
years) and aspirin-clopidogrel therapy (5.8 per 100 person-years)
than for aspirin alone (2.8 per 100 person-years) or clopidogrel
alone (2.5 per 100 person-years). Incidence rates within the ﬁrst
30 days were greater than those over the next 60 days for dual
antiplatelet therapy but not for single antiplatelet therapy after
adjustment for age and sex (ﬁgure).
Bias, confounding, and other reasons for caution
The study is a post hoc analysis of clinical trials. The RCTs did
not all thoroughly control medication intake.
Generalizability to other populations
The study may have underestimated bleeding risks because the
trials excluded patients at the highest risk of bleeding. The time
course of bleeding might diﬀer in older or frailer populations.
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